For patients struggling with obesity and its associated health challenges, Semaglutide GLP-1 offers a valuable therapeutic option
Broader clinical effects influence prescribing decisions, as some analyses report a 25% reduction in cardiovascular risk among people using semaglutide, which informs benefit-risk assessments beyond weight alone
Both carry a boxed warning about thyroid C-cell tumors observed in rodents, although this has not been demonstrated in humans
After an extensive process of reviewing studies, engaging in public debate and processing feedback, ICER concluded that semaglutide for weight loss should have an annual cost of $7,500 to $9,800, based on its potential benefits
With numerous criteria to consider, it can be confusing to determine which GLP-1 medication is ideal for each patient